Low Dose Naltrexone (LDN) Therapy Cost in Korea

Mijan Mijan • July 29, 2025

Low Dose Naltrexone (LDN) Therapy Cost in Korea

Low Dose Naltrexone (LDN) is increasingly being utilized in Korea as an adjunct therapy for autoimmune and chronic inflammatory conditions, including hidradenitis suppurativa, fibromyalgia, and psoriasis. Korean clinics incorporate LDN into integrative treatment plans due to its immune-modulating and anti-inflammatory properties. While it is not a mainstream treatment in all hospitals, specialized functional medicine clinics and some dermatology/immunology practices offer LDN prescriptions and monitoring for patients unresponsive to conventional therapies.

πŸ“Š Comprehensive Cost Overview

Therapy Type Monthly Cost (KRW) Use Case
Low Dose Naltrexone (1.5–4.5mg/day) 80,000 – 180,000 Autoimmune, chronic inflammatory skin disorders

πŸ” Detailed Cost Analysis by Component

Component Cost (KRW) Details
Initial Functional Medicine Consultation 50,000 – 100,000 Required for LDN eligibility and health review
LDN Compounded Prescription (30 Days) 80,000 – 180,000 Varies by compound pharmacy and dosage
Follow-up Appointment 30,000 – 60,000 Monthly monitoring and dose adjustment

βž• Additional & Optional Services Cost

Service Cost (KRW) Description
Lab Tests (Liver & Renal Function) 40,000 – 80,000 Recommended before and during treatment
Pharmacy Compounding Customization 10,000 – 30,000 For liquid or capsule formulations
Telemedicine Follow-up 20,000 – 40,000 Online consultation with prescription refill

πŸ₯ Clinical Treatment Costs

Facility Type Cost Range (KRW) Includes
Integrative Medicine Clinics 100,000 – 300,000 Full consultation + monthly LDN supply
Dermatology Clinics (with prescription rights) 80,000 – 200,000 Prescription and progress evaluation
Functional/Autoimmune Care Centers 150,000 – 400,000+ Customized care with diagnostics & labs
By Mijan Mijan August 8, 2025
By Mijan Mijan August 8, 2025
New paragraph
By Mijan Mijan August 8, 2025
By Mijan Mijan August 8, 2025
By Mijan Mijan August 8, 2025
By Mijan Mijan August 8, 2025
By Mijan Mijan August 8, 2025